Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

NCT01104155 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

123

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: eribulin mesylate + erlotinib
DRUG: eribulin mesylate + erlotinib

Sponsor

Eisai Inc.